TY - JOUR T1 - Considerations for clinical therapeutic development of statins for neurodevelopmental disorders JF - eneuro JO - eNeuro DO - 10.1523/ENEURO.0392-19.2020 SP - ENEURO.0392-19.2020 AU - Myrthe J. Ottenhoff AU - Lianne C. Krab AU - Ype Elgersma Y1 - 2020/02/12 UR - http://www.eneuro.org/content/early/2020/02/12/ENEURO.0392-19.2020.abstract N2 - Significance statementThe HMG-CoA reductase inhibitors lovastatin and simvastatin have both been investigated in clinical trials designed to treat the cognitive deficits associated with neurodevelopmental disorders such as Neurofibromatosis type 1, Fragile X and autism. In a recent study, the therapeutic efficacy of lovastatin and simvastatin were compared in a Fragile X (Fmr1) mouse model. The authors concluded that lovastatin was superior to simvastatin in rescuing the Fmr1 phenotypes, and cautioned against considering simvastatin as treatment for neurodevelopmental disorders. We discuss these findings in the context of published literature and argue that more support is needed for this potentially far-reaching conclusion. We further provide recommendations to improve the translation of pre-clinical studies of cognitive disorders into the clinical domain. ER -